Per this Brussels, Belgium MarketWire.com (Europe) feed, we see the talent drain continue, as the inevitable career uncertainty festers, in the newly-combined company:
. . . .UCB New Medicines today announced the appointment of Ismail Kola, Executive Vice President, UCB & President of UCB New MedicinesTM, UCB's discovery research through to 'proof of concept' organization. Ismail Kola will join UCB's Executive Committee with effect from November 23, 2009. . . .
Since March 2007, Dr. Kola has occupied the role of Senior Vice-President, Discovery Research and Early Clinical Research & Experimental Medicine, and Chief Scientific Officer at Schering-Plough. He came to Schering Plough from Merck where in January 2003 he was appointed Senior Vice President/Site Head, Basic Research. Prior to that, Ismail was Vice President, Research, and Global Head, Genomics Science and Biotechnology with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals where he was also a member of the Genomics Advisory Board. . . .
6 comments:
Ah, if only the walls could talk...an ex-Merck is not going back home? Why wouldn't he be welcomed?
Indeed, if only they could.
Namaste
I wonder what impact this news will have to Merck's decisions:
www.theday.com/article/20091110/NWS01/311109920/1017
New London research facility to close.
it's great to see fresh, creative ideas that have never been done before.
Ola, what's up amigos? :)
In first steps it's really good if someone supports you, so hope to meet friendly and helpful people here. Let me know if I can help you.
Thanks in advance and good luck! :)
You forgot Andrew Jackson’s Big Block of Cheese with nary a macaroni in sight.
Post a Comment